(00:32)
 Could you provide us a little background about yourself?

(01:44)
 Could you give us a brief overview of the new Mayo complete colorectal panel assay?

(03:44)
 Can you go a little bit into more detail on guidelines and therapeutic implications concerning these specific genes? 

 (06:09)
 Which patients should have this testing?

(08:00)
 Are there any last pieces you'd like to add about the new Mayo Clinic colorectal cancer assay?

(00:32)
 Could you provide us some background about yourself?

(01:34)
 Could you give us a brief overview of the new Mayo complete lung cancer assay?

(03:31)
 Can you talk a little bit more about the specific genes and why they're important for patient care?

(04:53)
 When would a clinician pathologist order a focused NGS panel, such as this new Mayo complete lung cancer panel, over a larger cancer panel? 

(07:27)
 What specimens are accepted for the Mayo complete lung cancer panel?

(08:50)
 How are these molecular results used in patient care?

(00:31)
 Could you tell us a little bit about yourself and your background?

(01:15)
 Can you give us a little understanding of this disease state and why a tailored evaluation for pediatric patients is important?

(02:47)
 What makes it more challenging to diagnose a pediatric autoimmune neurological disorder?

(03:32)
 Is the tailored evaluation necessary because different antibodies are evaluated?

(04:08)
 How common are these disorders in pediatric patients?

(04:40)
 How does our assay for adults differ from the pediatric assay?

(05:17)
 Do we evaluate for the ANNA-1 paraneoplastic antibody in both children and adults?

(05:59)
 Are our decisions on which antibodies to include based on our clinical experience?
 
(06:46)
 Which patients would this kind of testing be appropriate for?

(07:29)
 Should antibody testing be ordered early in the process of differential diagnosis?

(08:29)
 Do other disorders mimic these autoimmune disorders?

(09:00)
 What do test results mean in terms of next steps for physicians and patients?

(09:55)
 What are the most critical antibodies to test for in this pediatric population?

(10:30)
 Is it important for physicians to send both serum and CSF samples?

(10:48)
 In what specimen type is MOG most readily detected?

(11:18)
 What are the repercussions of not using a tailored evaluation?

(13:04)
 Do we use any patterns we see in test results to build future evaluations?

(14:15)
 Does a tailored evaluation mean faster test results?

(15:21)
 Are there any other key takeaways that you want to share with physicians to help them understand the importance of this evaluation and how it can be used in their clinical practices?

(0:32)
 Will you tell us a bit about yourself and your background?

(01:35)
 Can you help us understand what type of tests you perform in your laboratory and how the results can be used to support patient care?

(02:18)
 When is it important to consider urine drug testing, and what is our recommended approach?

(03:59)
 Could you help us understand more about forensic toxicology and when to consider testing?

(04:46)
 Is chain of custody testing recommended for only a small number of patients?

(04:58)
 What other tests are available, and where can people learn which testing to order? 

(00:32)
 Could you provide a little bit of background about yourself, please?

(01:01)
 Please give us a brief overview of the new PIK3CA assay.
 
(02:09) 
 Why do we offer two different tests, and when should each be ordered?

(03:58)
 Which patients should have this testing?

(04:39)
 Is this testing used for patients being considered for second-line treatment after first-line hormone receptor treatment?

(05:20)
 Is there anything else you would like to add about the PIK3CA testing?

(06:23)
 Why is it important to know the molecular signature of these tumors?